A myriad of AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health, a podcast by a16z Bio + Health and hosted by Kris Tatiossian and Olivia Webb, dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders, operators, and investors Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, along with distinguished guests like Mark Cuban, Greg ...
…
continue reading
コンテンツは Jon Chee によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Jon Chee またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!
Player FMアプリでオフラインにしPlayer FMう!
🧬 David Li - Meliora Therapeutics - Part 4 | Mechanism Identification in Biotech | AI & ML in Drug Development | Creating a New Method for Drug Discovery | Fundraising for Meliora | Building a Foundational Startup Team
Manage episode 428387618 series 3461709
コンテンツは Jon Chee によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Jon Chee またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
Part 4 of 4.
My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.
Before Meliora, David was Chief Business Officer at Everest Detection, an early detection liquid biopsy startup, and led commercial operations at Benchling, a life sciences software platform valued at $6 billion with over $500 million in funding.
David started his career in Goldman Sachs Healthcare Investment Banking Group and KKR's Private Equity Group, advising and investing in transactions exceeding $10 billion. His diverse financial and life sciences background offers valuable insights for founders.
Join us this week and hear about:
- David’s transition from private equity to co-founding Meliora and using AI/ML in drug development
- His fundraising experiences for Meliora and current outlook on the fundraising landscape in 2024
- His advice for aspiring entrepreneurs and reflections on “thinking big” in biotech
- Identifying mischaracterized mechanisms of action and establishing Meliora as a drug development company and computational platform
Please enjoy my conversation with David Li.
Timestamps:
00:28 Intro
02:00 Jason Scheltzer identifies mechanisms of action, the beginnings of Meliora
05:08 David meets Jason Scheltzer, forming Meliora with a thesis, as David becomes founding CEO and initial fundraising begins
07:20 David’s serendipitous meeting with Jason, getting on board as more than an investor
09:16 Building the early founding team at Meliora, establishing Meliora as a drug company
12:05 How Meliora is disrupting the status quo in drug discovery and development
17:24 David’s approach to building an internal pipeline and BD partnerships
19:49 David’s experience fundraising and his outlook on fundraising in 2024
22:21 Meloria’s 2-year vision, transitioning from Seed to Series A
24:03 Shoutouts and advice to 21-year old self
26:23 Outro
Find Our Guest, David Li, at these links:
Find Our Host, Jon Chee, at these links:
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Topics Mentioned:
Benchling https://www.benchling.com/
Meliora Therapeutics https://www.melioratherapeutics.com/
Everest Detection https://everestdetection.com/
AstraZeneca https://www.astrazeneca.com/
Tagrisso https://www.tagrisso.com/
Drug candidates that were mischaracterized https://ergobio.substack.com/p/meliora-therapeutics-is-building
Series A, B, & C Rounds https://www.excedr.com/resources/series-funding-explained
Biotech Fundraising https://www.excedr.com/resources/biotech-startup-funding-options
Computational Platforms in Biotech https://www.nfx.com/post/bioplatforms-computational-biology
People Mentioned:
Jason Sheltzer https://www.linkedin.com/in/jason-sheltzer-ba0086234/
Joan Smith https://www.linkedin.com/in/joanclarasmith/
Claudio Chuaqui https://www.linkedin.com/in/claudio-chuaqui-5612381/
Andrew Coopersmith https://www.linkedin.com/in/andrew-s-coopersmith/
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
88 つのエピソード
Manage episode 428387618 series 3461709
コンテンツは Jon Chee によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Jon Chee またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
Part 4 of 4.
My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.
Before Meliora, David was Chief Business Officer at Everest Detection, an early detection liquid biopsy startup, and led commercial operations at Benchling, a life sciences software platform valued at $6 billion with over $500 million in funding.
David started his career in Goldman Sachs Healthcare Investment Banking Group and KKR's Private Equity Group, advising and investing in transactions exceeding $10 billion. His diverse financial and life sciences background offers valuable insights for founders.
Join us this week and hear about:
- David’s transition from private equity to co-founding Meliora and using AI/ML in drug development
- His fundraising experiences for Meliora and current outlook on the fundraising landscape in 2024
- His advice for aspiring entrepreneurs and reflections on “thinking big” in biotech
- Identifying mischaracterized mechanisms of action and establishing Meliora as a drug development company and computational platform
Please enjoy my conversation with David Li.
Timestamps:
00:28 Intro
02:00 Jason Scheltzer identifies mechanisms of action, the beginnings of Meliora
05:08 David meets Jason Scheltzer, forming Meliora with a thesis, as David becomes founding CEO and initial fundraising begins
07:20 David’s serendipitous meeting with Jason, getting on board as more than an investor
09:16 Building the early founding team at Meliora, establishing Meliora as a drug company
12:05 How Meliora is disrupting the status quo in drug discovery and development
17:24 David’s approach to building an internal pipeline and BD partnerships
19:49 David’s experience fundraising and his outlook on fundraising in 2024
22:21 Meloria’s 2-year vision, transitioning from Seed to Series A
24:03 Shoutouts and advice to 21-year old self
26:23 Outro
Find Our Guest, David Li, at these links:
Find Our Host, Jon Chee, at these links:
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Topics Mentioned:
Benchling https://www.benchling.com/
Meliora Therapeutics https://www.melioratherapeutics.com/
Everest Detection https://everestdetection.com/
AstraZeneca https://www.astrazeneca.com/
Tagrisso https://www.tagrisso.com/
Drug candidates that were mischaracterized https://ergobio.substack.com/p/meliora-therapeutics-is-building
Series A, B, & C Rounds https://www.excedr.com/resources/series-funding-explained
Biotech Fundraising https://www.excedr.com/resources/biotech-startup-funding-options
Computational Platforms in Biotech https://www.nfx.com/post/bioplatforms-computational-biology
People Mentioned:
Jason Sheltzer https://www.linkedin.com/in/jason-sheltzer-ba0086234/
Joan Smith https://www.linkedin.com/in/joanclarasmith/
Claudio Chuaqui https://www.linkedin.com/in/claudio-chuaqui-5612381/
Andrew Coopersmith https://www.linkedin.com/in/andrew-s-coopersmith/
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
88 つのエピソード
Todos os episódios
×プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。